文献速递骨质疏松与代谢性骨病关节外科

类风湿关节炎患者使用TNF抑制剂与其他生物制剂后骨质疏松性骨折风险比较:一项队列研究

Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study.
PubMed 文献 · Osteoporos Int · 2020-06-08

该研究基于韩国国家健康保险服务2002至2016年数据,纳入首次使用TNF抑制剂、阿巴西普或托珠单抗的类风湿关节炎患者,经倾向评分匹配后比较骨质疏松性骨折风险。结果显示,TNF抑制剂与阿巴西普或托珠单抗相比,骨折风险无显著差异,主要终点风险比分别为0.91(95%CI 0.48-1.71)和1.00(95%CI 0.55-1.83)。

要点

  • TNF抑制剂与阿巴西普相比骨折风险无显著差异,HR为0.91(95%CI 0.48-1.71)。
  • TNF抑制剂与托珠单抗相比骨折风险无显著差异,HR为1.00(95%CI 0.55-1.83)。
  • 椎体和非椎体骨折的次要分析结果与主要终点一致。

核心结论

  • 在类风湿关节炎患者中,TNF抑制剂与阿巴西普或托珠单抗相比,骨质疏松性骨折风险无显著差异。

研究设计与样本

  • 基于韩国国家健康保险服务2002至2016年数据的人群队列研究,纳入首次使用TNF抑制剂、阿巴西普或托珠单抗的类风湿关节炎患者,采用可变比例倾向评分匹配(最多10名TNF抑制剂使用者匹配1名对照药物使用者)调整50余项基线混杂因素,并用Cox比例风险模型估计风险比。

主要发现

  • 倾向评分匹配后,2307名TNF抑制剂使用者与588名阿巴西普使用者匹配,2462名TNF抑制剂使用者与640名托珠单抗使用者匹配。
  • TNF抑制剂与阿巴西普匹配组平均随访454天期间共发生77例骨折,TNF抑制剂与托珠单抗匹配组平均随访461天期间共发生83例骨折。
  • TNF抑制剂与阿巴西普比较的倾向评分匹配HR为0.91(95%CI 0.48-1.71),与托珠单抗比较的HR为1.00(95%CI 0.55-1.83)。
  • 椎体骨折和非椎体骨折的次要分析结果与主要终点相似。

临床怎么用

  • 在类风湿关节炎患者选择生物制剂时,TNF抑制剂与阿巴西普或托珠单抗之间的骨质疏松性骨折风险差异不显著,可作为个体化决策的参考信息。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: In this population-based cohort study on comparative osteoporotic fracture risks between different biologic disease-modifying drugs among patients with rheumatoid arthritis (RA), we did not find a significant difference in the risk of osteoporotic fractures between RA patients receiving TNF inhibitors versus abatacept or tocilizumab. INTRODUCTION: We aimed to investigate the comparative risk of osteoporotic fractures between rheumatoid arthritis (RA) patients who initiated TNF inhibitors (TNFis) versus abatacept or tocilizumab. METHODS: Using the Korea National Health Insurance Service datasets from 2002 to 2016, RA patients who initiated TNFis, abatacept, or tocilizumab were identified. The primary outcome was a composite end point of non-vertebral fractures and hospitalized vertebral fractures; secondary outcomes were two components of the primary outcome and fractures occurring at the humerus/forearm. Propensity score (PS) matching with a variable ratio up to 10 TNFi initiators per 1 comparator drug initiator was used to adjust for > 50 baseline confounders. We estimated hazard ratios (HRs) and 95% confidence interval (CI) of fractures comparing TNFi initiators to abatacept and to tocilizumab by Cox proportional hazard models stratified by a matching ratio. RESULTS: After PS-matching, 2307 TNFi initiators PS-matched on 588 abatacept initiators, and 2462 TNFi initiators on 640 tocilizumab initiators were included. A total of 77 fractures occurred during a mean follow-up of 454 days among TNFi and abatacept initiators and 83 fractures during 461 days among TNFi and tocilizumab initiators. The PS-matched HR (95% CI) was 0.91 (0.48-1.71) comparing TNFi versus abatacept initiators, and 1.00 (0.55-1.83) comparing TNFi versus tocilizumab initiators. Analysis on vertebral and non-vertebral fractures showed similar results. CONCLUSIONS: In this nationally representative cohort, we did not find a significant difference in the risk of fractures between TNFi initiators versus abatacept or tocilizumab among RA patients.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Shin A, Park EH, Dong YH, et al. Comparative risk of osteoporotic fracture among patients with rheumatoid arthritis receiving TNF inhibitors versus other biologics: a cohort study. Osteoporos Int. 2020. PMID: 32514765. doi:10.1007/s00198-020-05488-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。